altretamine/cisplatin/cyclophosphamide protocol – Talk Bio

Actionable Insights Powered by AI

AstraZeneca Acquires Complete Global Rights to AbelZeta’s C-CAR031 CAR-T Therapy for Up to $630 Million

1 week ago talkbio0Tagged AbelZeta, altretamine/cisplatin/cyclophosphamide protocol, AstraZeneca, C-CAR031, CAR-T, China, GPC3 protein, human, Liver carcinoma

AstraZeneca; AbelZeta; C-CAR031; CAR-T; GPC3; China rights; $630M; hepatocellular carcinoma; HCC

Tempest Seeks Strategic Partners to Launch Phase 3 Liver Cancer Trial Amid Funding Challenges

10 months ago talkbio0Tagged altretamine/cisplatin/cyclophosphamide protocol, amezalpat, Avastin, biotech, Clearance, Clinical Oncology, Liver and Intrahepatic Biliary Tract Carcinoma, partnerships, Peroxisome Proliferator-Activated Receptors, Phase 3 trial, strategic, Tecentriq, United States Food and Drug Administration

Tempest Therapeutics , Amezalpat , Phase 3 Trial , Liver Cancer (HCC) , Strategic Partnerships , Biotech Funding , PPAR⍺ Antagonist , Clinical Oncology , FDA Clearance , Tecentriq and Avastin Combination Therapy